VivoSeq
Other

Premenopausal

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Premenopausal is an early-stage landscape with 0 programs across 4 companies. The most active players are Merck & Co., AbbVie, Xiamen Amoytop Biotech Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalX

Xiamen Amoytop Biotech Co., Ltd.

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed10 · 77%
Terminated1 · 8%
Unknown status1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Romosozumab/Denosumab Study for Premenopausal IOP
Active, not recruiting·—·Phase 2·NCT04800367·30 enrolled
Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants
Completed·MMyovant Sciences GmbH·Phase 1·NCT04978688·48 enrolled
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309478·1,099 enrolled
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC
Completed·National Cancer Center, Korea·Phase 2·NCT00532272·78 enrolled
An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females
Completed·AbbVie logoAbbVie·Phase 1·NCT01403038·216 enrolled
Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02317809·34 enrolled
An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT07269327·24 enrolled
A Study of HS-10518 in Healthy Adult Premenopausal Females in China
Completed·WWest China Second University Hospital·Phase 1·NCT07264192·60 enrolled
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 1·NCT06893796·18 enrolled
Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02175394·18 enrolled
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
Completed·—·Phase 2·NCT00004400·56 enrolled
Premenopausal Endocrine Responsive Chemotherapy Trial
Terminated·EETOP IBCSG Partners Foundation·Phase 3·NCT00066807·29 enrolled
Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide
Unknown status·—·Phase 2·NCT03475758·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)